Skip to main content
Retour
IMNM logo

Immunome, Inc.

Qualité des données : 100%
IMNM
NASDAQ Healthcare Biotechnology
20,21 €
▼ 0,54 € (-2,60%)
Cap. Boursière : 1,78B
Fourchette du Jour
19,91 € 21,17 €
Fourchette 52 Semaines
5,15 € 27,65 €
Volume
1 181 672
Moyenne 50J / 200J
22,70 € / 15,69 €
Clôture Précédente
20,75 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -8,4 0,4
P/B 2,8 2,9
ROE % -52,1 3,9
Net Margin % -3060,0 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
36,83 € +82.2%
Low: 32,00 € High: 40,00 €
BPA Prévisionnel
-2,41 €
CA Est.
4,4 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 1,36 €
-0,14 € – 3,69 €
620 M 6
FY2029 -0,06 €
-0,16 € – 0,01 €
400 M 6
FY2028 -1,18 €
-2,86 € – -0,48 €
240 M 8

Points Clés

Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -200,60M
PEG of 0,17 suggests growth is underpriced
Capital intensive — 139,53% of revenue goes to capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-23,23%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-52,09%
ROIC-25,16%
Net Margin-3059,99%
Op. Margin-3084,76%

Sécurité

Debt / Equity
0,01
Current Ratio14,69
Interest Coverage0,00

Valorisation

P/E Ratio
-8,36
P/B Ratio2,80
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -23,23% Revenue Growth (3Y) -29,63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 6,94M Net Income (TTM) -212,39M
ROE -52,09% ROA -31,09%
Gross Margin 57,43% Operating Margin -3084,76%
Net Margin -3059,99% Free Cash Flow (TTM) -200,60M
ROIC -25,16% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 14,69
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -8,36 P/B Ratio 2,80
P/S Ratio 255,82 PEG Ratio 0,17
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,78B Enterprise Value 1,13B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6,94M 9,04M 14,02M 0,0 0,0
Net Income -212,39M -292,96M -106,81M -36,90M -24,71M
EPS (Diluted) -2,43 -5,00 -5,38 -3,09 -2,14
Gross Profit 3,99M 9,04M 14,02M 0,0 0,0
Operating Income -214,11M -305,80M -109,53M -36,90M -25,20M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 683,19M 240,24M 148,54M 24,05M 57,93M
Total Liabilities 48,85M 59,08M 28,66M 7,39M 9,74M
Shareholders' Equity 634,34M 181,17M 119,88M 16,65M 48,19M
Total Debt 3,86M 4,83M 1,65M 291 000,0 317 000,0
Cash & Equivalents 653,48M 143,35M 98,68M 20,32M 49,23M
Current Assets 660,78M 221,34M 144,70M 22,65M 56,64M
Current Liabilities 44,99M 54,31M 21,83M 7,33M 9,73M